Fundamental Analysis of Cyclacel Pharmaceuticals Inc - Growth / Value Index
CYCC - Valuation Highlights
Valuation Analysis
Price to Book Ratio is 0.610 indicating that it is undervalued.
Tsr Value Index - Poor Score of 34.38
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -0.153 | -0.079 | -201.41 % | |
| Price to Book | 0.630 | 3.21 | -88.42 % | -1.35 |
| Price to Sales | 28.72 | 5.01 | 236.80 % | |
| Enterprise Value to EBITDA Multiple | 0.0014 | 0.058 | 277.71 % |
CYCC - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Very Poor Score of 5.00
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -411.50 | -4069.69 | 97.02 % | 0 |
| Return On Asset | -144.70 | -280.56 | 99.64 % | -47.79 |
| Net Profit Margin | -18749.36 | -6350.39 | -11.74 % | -10158.62 |
| Operating Profit Margin | -26043.82 | -7439.07 | -0.332 % | -25103.45 |
| EBITDA Margin | -26177.38 | -6342.42 | -43.82 % | -25096.55 |
Highlights
| Market Cap | 3350.87 K |
| Enterprise Value | -27134.60 |
| Price/Book TTM | 0.630 |
| Outstanding Share | 1463.26 K |
| Float/ Outstanding Share | 79.21% |
| Dividend Yield | 2.82 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | -77.16 |
| Sloan Ratio | -0.833 |
| Peter Lynch Fair Value | 0 |
CYCC - Growth Highlights
Growth Analysis
Short term positive trend in total sale and net profit
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 76373.00 | 4.29 % | 6.45 % |
| Gross Profit | 74373.00 | 1412.50 % | 12.90 % |
| EBITDA | -19992.45 K | 49.99 % | 26.35 % |
| Net Profit | -14319.45 K | 16.53 % | 44.11 % |
| EPS | -14.95 | 66.82 % | NA |
CYCC - Stability Highlights
Stability Analysis
Company is Debt Free
Altman Z Score of -77.10 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0 | 0 % | 0 |
| Cash Ratio | 0.414 | -83.32 % | |
| Quick Ratio | 0 | 0 % | 0.579 |
| Shareholders Equity | 6.89 | -87.78 % | |
| Debt to EBITDA | 0 | 0 % |
Historical Valuation Ratios of Cyclacel Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Cyclacel Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Cyclacel Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Cyclacel Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)